Cost Reduction And EBITDA TrajectoryAggressive restructuring and realized operating efficiencies are lowering costs and supporting the company’s path toward EBITDA break-even and positive cash flow in 2026.
Gross Margin ExpansionDeployment of the Converge platform is shifting sales toward higher-margin plan customers and driving materially higher gross margins, improving profitability per contract.
Product Innovation And ScalabilityAI-driven automation of patient intake and a standardized software-plus-services model are expected to boost client ROI and make the platform more scalable, supporting future share gains.